Screener
Vertex Pharmaceuticals VRTX U.S. tax on foreign earnings, net of credits
U.S. tax on foreign earnings, net of credits at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept vrtx:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarningsNetPercent.
The source filing: Vertex Pharmaceuticals’s 10-K, filed February 13, 2026.
- Filed
- Feb 13, 2026, 4:20 PM EST
- Fiscal year
- FY2025
- Accession
- 0000875320-26-000056
| Line item | Year ended December 31, 2024 | Year ended December 31, 2023 |
|---|---|---|
| Federal statutory tax rate | 21.0% | 21.0% |
| State taxes, net of federal benefit | 29.5% | 0.3% |
| Foreign income tax rate differential | 21.3% | (0.6)% |
| U.S. tax on foreign earnings, net of credits | (12.6)% | 0.7% |
| Foreign derived intangible income deduction | (28.3)% | (1.7)% |
| Tax credits | (102.9)% | (6.0)% |
| Stock compensation (benefit), shortfalls and cancellations | (25.5)% | (0.8)% |
| Uncertain tax positions | 11.3% | 3.4% |
ITEM 16.FORM 10-K SUMMARY
FAQ
- What is Vertex Pharmaceuticals's U.S. tax on foreign earnings, net of credits?
- Vertex Pharmaceuticals (VRTX) reported U.S. tax on foreign earnings, net of credits of -12.6% in Q4 2024.
- What does U.S. tax on foreign earnings, net of credits mean?
- This metric measures the U.S. tax impact on foreign earnings, net of applicable foreign tax credits. It reflects the tax cost or benefit associated with the repatriation or taxation of international profits under current tax laws.
Ask your AI about Vertex Pharmaceuticals's u.s. tax on foreign earnings, net of credits.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude